and either Type 2 diabetes mellitus or previous kidney transplantation were randomized to low-dose continuous erythropoiesis receptor activator (CERA; monthly dose 30-75 mg; n ¼ 115) or placebo (n ¼ 120). The primary endpoint was the annual change in eGFR (abbreviated Modification of Diet in Renal Disease formula). Results. Mean (standard deviation) eGFR was 40.7 (9.8) mL/ min/1.73 m 2 versus 39.8 (9.2) mL/min/1.73 m 2 at baseline for CERA and placebo, respectively, and 39.0 (11.6) g/dL versus 39.7 (10.6) g/dL at the final visit. The median (interquartile range) annual reduction in eGFR was 0.5 (À2.2, 3.8) mL/min/ 1.73 m 2 with CERA versus 0.4 (À2.0, 3.2) mL/min/1.73 m 2 with placebo (P ¼ 0.657). No significant difference in the annual change in eGFR was observed between treatment groups in the subpopulations with Type 2 diabetes or kidney transplant. Adverse events with a suspected relation to study drug occurred in 22.0% and 16.2% of patients randomized to CERA or placebo, respectively, and adverse events led to study drug discontinuation in 11.0% and 8.5% of patients. Conclusions. Patients with moderate CKD and Type 2 diabetes or previous kidney transplantation showed stable renal function that was unaffected by administration of low-dose ESA. In addition, there was no clinically meaningful effect of 2-year lowdose ESA treatment on albuminuria, an important surrogate marker of kidney injury.
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I N T R O D U C T I O N
Anaemia in patients with chronic kidney disease (CKD) reduces quality of life [1] and is associated with an increased risk of cardiovascular events [2] . The presence of anaemia is also associated with more rapid progression to end-stage renal disease [3, 4] , an effect that could be attributed to increased oxidative stress and tubulointerstitial damage arising from hypoxia of tubular cells [5] . Correction of anaemia by erythropoiesis-stimulating agents (ESAs) is routine practice for patients with CKD, but the nonerythropoietic effects of ESA therapy are being increasingly recognized. These include a reduction of oxidative stress and suppression of apoptosis of renal endothelial cells [6] [7] [8] , which could potentially ameliorate the progressive decline of kidney function.
Landmark trials of ESA therapy in CKD populations (CREATE [9] , CHOIR [10] , ACORD [11] and TREAT [12] ) were undertaken to correct anaemia and used cardiovascular outcomes as their primary endpoints [9] [10] [11] [12] . Secondary endpoint analysis showed that ESA therapy versus placebo [12] , or use of ESA to target higher versus lower haemoglobin (Hb) values [9, 10] , exerted no effect on progression to renal replacement therapy. Data regarding the change in estimated glomerular filtration rate (eGFR) over time with higher or lower Hb targets was mixed [9, 13] . Several smaller randomized trials of various lengths have investigated the effect of standard (or high) doses of ESA on various renal endpoints in patients with non-dialysis CKD and anaemia [14] [15] [16] . Results showed some evidence for delayed progression of renal disease [14, 16] , but the study designs make it impossible to disentangle a possible influence of non-haematopoietic effects from the established renal benefits of anaemia correction [4] . A post hoc analysis of 2434 patients with non-dialysis CKD taking part in the prospective Co-JET study observed that ESA administration delayed progression to dialysis, but this was not a pre-specified endpoint [17] . It is feasible that early intervention with ESA therapy even in non-anaemic patients may delay progression of CKD, but this has not been explored to date. A recent metaanalysis, which may not have included all relevant studies (e.g. the TREAT trial [12] ), was unable to conclusively evaluate the effect of ESAs on progression of kidney disease or delay in onset of dialysis, but outcomes measures showed no statistically significant difference between ESA therapy versus placebo or no treatment [18] .
The 2-year PRIMAVERA study prospectively assessed whether early initiation of ESA treatment could delay the progression of renal function loss. This randomized trial was undertaken in patients with moderate CKD (stage 3) who, at the time of protocol development, were considered to be at high risk for renal deterioration, and used a lower initial dose of the ESA agent continuous erythropoiesis receptor activator (CERA; 30 lg) than is typically used for anaemia management in this setting.
M A T E R I A L S A N D M E T H O D S
Study design
PRIMAVERA was a randomized, placebo-controlled, singleblind, 24-month trial undertaken at 30 nephrology and transplant centres in Germany from August 2010 to March 2015 (NCT01194154) [19] . Written informed consent was obtained from all patients following approval from the German federal health authority, the lead ethics committee at the Saarland University Medical Center, and the ethics committee at all study centres. The deadline for recruitment was extended from December 2011 to March 2013 in response to slow patient enrolment and study drug supply problems.
Study objective
The primary objective of the study was to investigate the nephroprotective effect of early treatment with low-dose CERA on the annual decline in kidney function in patients with moderate CKD stage 3 in two specific populations considered to be at increased risk for renal deterioration: patients with Type 2 diabetes [20] and recipients of a kidney transplant [21] .
Eligibility criteria
Patients aged 18 years or older were eligible for study entry if they had estimated eGFR between 30 and 59 mL/min/1.73 m 2 [abbreviated Modification of Diet in Renal Disease (MDRD) equation [22] ] measured centrally at the screening visit or as part of routine management within the month prior to screening) with urinary albumin-creatinine ratio <3000 mg/g creatinine or total urine protein <3000 mg/24 h. Patients were required to have confirmed Type 2 diabetes mellitus or have undergone kidney transplantation at least 6 months prior to study entry. The key exclusion criteria were Hb level <11 g/dL or >14 g/dL, mean systolic blood pressure >140 mmHg or mean diastolic blood pressure >90 mmHg, initiation of antihypertensive treatment with an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or aliskiren <3 months before screening, iron deficiency as measured by serum ferritin and transferrin saturation despite adequate treatment, organ transplantation other than kidney, myocardial infarction or stroke <6 months prior to inclusion, severe and unstable coronary artery disease, chronic congestive heart failure (New York Heart Association Class III to IV), chronic, uncontrolled or symptomatic inflammatory disease, acute infection or sepsis, C-reactive protein >15 mg/L, and apparent vitamin B 12 or folic acid deficiency despite adequate treatment. Inclusion criteria were modified in three successive protocol amendments to improve recruitment rates. The changes included removing or revising the following criteria from the initial study protocol: kidney transplantation to have been performed 10 years previously, urinary albumin-creatinine ratio >50 and <3000 mg/g creatinine or total urinary protein <3000 mg/24 h.
Study treatment
Patients were stratified according to the presence of Type 2 diabetes or previous kidney transplant and then randomized by a computerized system in a 1:1 ratio to receive CERA or matching placebo. Patients remained blinded to treatment throughout the study period. Patients who discontinued study medication were withdrawn from the study.
Patients randomized to the active treatment arm received CERA (MirceraV R ) manufactured by Roche Diagnostics GmbH, Mannheim, Germany, and packaged by GP Grenzach Produktions GmbH, Grenzach-Wyhlen, Germany. CERA was administered once a month using pre-filled syringes containing 30 lg, 50 lg or 75 lg. The starting dose was 30 mg. After the first two visits, the physician was to adjust the dose as required to maintain Hb concentration within 61.5 g/dL of the baseline value, by increasing the dose to the next higher strength if a decrease of >1.0 g/dL was required or decreasing the dose to the next lower strength if an increase of >1.0 g/L was required (or by skipping one dose as per pre-defined criteria).
Study endpoints
The primary endpoint was the annual change in eGFR, using the abbreviated MDRD formula [21] . Secondary efficacy endpoints were the annual change in eGFR calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [23] and change from baseline in serum creatinine, urinary albumin-creatinine ratio and serum cystatin C. Baseline values were obtained at the first post-screening study visit, prior to the first dose of study medication. Safety was assessed based on adverse events and on discontinuation of study drug due to either Hb increase >1.5 g/dL from baseline at two consecutive visits despite use of lowest CERA dose or an increase in blood pressure to >150 mmHg systolic or >100 mmg diastolic on two consecutive visits. Centrally analysed values for eGFR and Hb are reported.
Statistical analysis
The initial sample size calculation indicated that analysis of 200 patients with Type 2 diabetes and 200 transplant recipients, allowing for 28% drop-outs, would provide 90% power to detect a clinically relevant difference of 1.5 mL/min/1.73 m 2 with a standard deviation of 2.75 mL/min/1.73 m 2 [19] in the annual reduction in eGFR between treatment groups within both subpopulations assuming that the placebo group would show a 2-3 mL/min/1.73 m 2 annual reduction in eGFR [24, 25] . Due to slow recruitment, the planned population size was reduced by a protocol amendment in June 2012 from 400 patients to 240 patients and the number of centres was increased from a maximum of 25 to 30, with at least 6 patients per centre instead of the original 15 patients. This reduced the statistical power from 90% to 80%.
The primary endpoint, annual change in eGFR (MDRD), was analysed overall and separately for the diabetes and transplant subgroups based on the intent-to-treat (ITT) population, defined as all randomized patients who received at least one dose of study medication and provided at least one postbaseline eGFR value. The primary analysis was performed by a two-step approach: (i) the annual reduction in eGFR was calculated for each patient based on linear regression; and (ii) the annual reduction rate was compared between treatment groups based on the non-parametric Wilcoxon rank sum test at the 5% significance level (two-sided). All secondary efficacy endpoints were analysed in the same population as the primary endpoint. Safety analyses were descriptive and were based on the safety population, defined as all randomized patients who received at least one dose of study medication (based on actual medication administered).
Statistical analyses were performed using SAS V R (Version 9.4; SAS Institute Inc., Cary, NC, USA).
R E S U L T S
Patient population
In total, 426 patients were screened, of whom 241 patient met the eligibility criteria and were randomized (117 CERA, 124 placebo). Of these, 235 received at least one dose of study drug and provided at least one post-baseline eGFR value, and formed the ITT population (Figure 1) . The safety population also included 235 patients: 118 patients who received CERA and 117 patients who received placebo (three subjects randomized to placebo each incorrectly received a single dose of CERA).
The 24-month study was completed by 159 patients, with adverse events and Hb increase being the most frequent reasons for premature discontinuation (Figure 1 ). There were no significant differences between groups concerning the causes of discontinuation other than a higher rate of Hb increase in the CERA group (P ¼ 0.020). Overall, 196 patients had no major protocol deviations (94 CERA, 102 placebo). The most common major protocol deviation was treatment for <6 months (14 CERA, 9 placebo).
The demographics and baseline characteristics of the two treatment groups were well balanced ( Table 1) . Characteristics of the two treatment groups were also similar within the subpopulations of patients with diabetes or previous transplant (Supplementary Table S1 ).
Study treatment and concomitant medication
All patients who received CERA were given a first dose of 30 lg. The proportion of patients given a 30-lg dose at subsequent study visits ranged from 93.9% to 78.3% (Supplementary Table S2 ). The maximum monthly dose did not exceed 75 lg in any patient during the study, and no more than eight and three patients, respectively, were receiving a dose of 50 lg or 75 lg at any study visit. The mean monthly dose remained stable during the study: mean standard deviation (SD) values were 30.0 (0) lg at month 1, 29.9 (11.4) lg at month 12 and 29.6 (12.8) lg at the final dose (administered at month 23).
Use of medication acting on the renin-angiotesin system during the study was reported by investigators in 81.7% of CERA-treated patients and 83.3% of placebo-treated patients. Administration of iron supplements was reported infrequently (CERA 9.6%, placebo 9.2%).
Hb status
Mean (SD) Hb at baseline was 12.7 (1.0) g/dL in the CERA group and 12.9 (1.0) g/dL in the placebo group. In total, 7 patients (3.0%) had Hb <11 g/dL at baseline and 27 patients (11.5%) had Hb >14 g/dL at baseline, against protocol; no patient had an Hb value <10.0 g/dL or >15.1 g/dL (Table 1) . By month 3, there was a minor increase in the CERA cohort in the placebo group. eGFR remained stable in both groups during the study (Figure 2 ). At the final study visit, mean (SD) eGFR was 39.0 (11.6) g/dL and 39.7 (10.6) g/dL in the CERA and placebo groups, respectively (Table 2) . The between-group difference was not significantly different (P ¼ 0.657). The annual change in eGFR was also similar between groups when GFR was estimated using the CKD-EPI formula (Table 2) . When the primary analysis was repeated in the subpopulation of patients with no major protocol deviations (94 CERA, 102 placebo), the (Table 2 ). eGFR remained stable in both subgroups during the study (Supplementary Figure S1) . As in the total study population, there were no significant differences between treatment groups in terms of the annual change in eGFR (Table 2) . Reason for transfusion was not captured. c Seven patients had Hb <11 g/dL at baseline when measured centrally, against protocol (4 CERA, 3 placebo), all of whom were in the range 10.0-10.9 g/dL. A further 27 patients had baseline Hb >14 g/dL at baseline (12 CERA, 15 placebo), all but one of whom was in the range 14.1-14.9 g/dL (the final patient had a baseline Hb of 15.1 g/dL).
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Changes in serum creatinine, urinary albumin-creatinine ratio and serum cystatin C from baseline to the final study visit were also similar between treatment groups (Supplementary Table S3 ). For the urinary albumin-creatinine ratio, the median change from baseline to the final visit was À4 mg/g (range À1019 to 2560 mg/g) in the CERA group and 8 mg/g (range À2720, 2536 mg/g) in the placebo group.
Safety
In the safety population, one or more adverse event was reported in 84.7% (100/118) of patients in the CERA group and 86.3% (101/117) of patients in the placebo arm. The most frequently reported adverse events were nasopharyngitis, cough, urinary tract infection, diarrhoea, peripheral oedema and hypertension (Supplementary Table S4 ). Adverse events with a suspected relation to study drug occurred in 22.0% and 16.2% of patients randomized to CERA or placebo, respectively. The most frequent of these in the CERA cohort were increased Hb (n ¼ 3) and hypertension (n ¼ 5); the most common event in the placebo group was nasopharyngitis (n ¼ 3; Table 3 ). Serious adverse events with a suspected relation to study drug occurred in eight patients (6.8%) in the CERA group (dyspnoea [2] , cardiac arrest, chest pain, sudden death, transient global amnesia, decreased Hb and renal failure), with seven events in six L o w -d o s e E S A a n d p r o g r e s s i o n o f r e n a l d y s f u n c t i o n placebo-treated patients (5.1%; atrial flutter, influenza, urinary tract infection, adenocarcinoma, lipoma, cerebrovascular accident and diabetes mellitus). Adverse events led to study drug discontinuation in 13 CERA-treated patients (11.0%) and 10 placebo-treated patients (8.5%). No adverse event resulted in discontinuation in more than one patient in either group other than increased Hb (two patients in the CERA group) and anaemia (three patients in the placebo arm).
In total, 12 patients in the CERA group (10.2%) and 3 in the placebo arm (2.6%) discontinued study drug and withdrew from the study due to Hb increase >1.5 g/dL from baseline at two consecutive visits despite use of lowest CERA dose. Withdrawal as a result of blood pressure increasing to >150 mmHg systolic or >100 mmg diastolic on two consecutive visits occurred in five CERA-treated patients (4.2%) and three placebo-treated patients (2.6%).
D I S C U S S I O N
In this randomized, placebo-controlled trial, early initiation of low-dose ESA treatment in non-anaemic patients with moderate CKD did not significantly affect the progression of kidney disease, as assessed by the annual change in eGFR, over a 2-year period. Additionally, no effect of 2-year treatment with lowdose ESA affected albuminuria, an important marker for kidney injury, a finding that conflicts with published data based on animal studies [26, 27] . However, the study design-in particular, the choice of patients-precludes any firm conclusion that lowdose ESA therapy does not delay or diminish renal deterioration.
The study selected two distinct populations, patients with Type 2 diabetes and patients who had undergone kidney transplantation, all of whom were required to have eGFR in the range 30-59 mL/min/1.73 m 2 , with significant albuminuria, at study entry. A series of reports on kidney failure risk equations has identified such patients as being a higher risk for CKD progression [28] [29] [30] [31] , and this enhanced risk is recognized in the KDIGO Clinical Practice Guideline [32] . This decision was made on the basis that the patients randomized to the control arm were expected to show a progressive loss of renal function over the study period. In fact, mean eGFR remained virtually unchanged in the placebo-treated group over the 2-year study, negating any chance to show a benefit for ESA therapy. The progression of CKD is well known to vary according to the underlying pathology, but even for individuals with the same diagnosis there is wide variability in the rate of deterioration [33, 34] . Patients with Type 2 diabetes show a highly heterogeneous course in terms of renal function over time, with only a subset of patients (notably those with more advanced diabetic glomerulopathy) showing rapid deterioration [35] . One study of Type 2 diabetes patients with eGFR !60 mL/min/1.73 m 2 found that only 10.4% showed a decline in eGFR after 8-year follow-up [36] . Lifestyle factors [37, 38] and intensity of diabetes management [39] , for example, influence the risk for worsening CKD in Type 2 diabetes. The presence of microalbuminuria or proteinuria at baseline does not distinguish reliably between those at high or low risk of progression [35] ; instead, biopsy findings [35] , or possibly the presence of other diabetes-related complications such as retinopathy [36, 40] , are required to identify those likely to show rapid loss of function. In our cohort of patients with diabetes, only 27.4% were reported to have diabetic nephropathy. It is likely that many of the other patients with diabetes had developed CKD secondary to other conditions, predominantly hypertensive nephrosclerosis, for which progression to end-stage renal disease is relatively benign. Based on recent evidence, it appears that the expected annual decrease of 2-3 mL/min/1.73 m 2 in eGFR in the control patients with diabetes was overestimated [40, 41] . For kidney transplant patients, similarly, the expectation of declining eGFR was misplaced. Recent studies of maintenance kidney transplant patients have shown kidney function to remain relatively stable for up to 2 years under standard immunosuppressive regimens [42, 43] , consistent with our observations. Kidney transplant recipients are a diverse group, with multiple donor and recipient factors influencing loss of eGFR over time [44, 45] . The situation is further complicated by post-transplant clinical events unrelated to ESA therapy, such as allograft rejection [46] , which could adversely affect graft function and confound results by inducing a non-linear loss of renal function.
With hindsight, more discriminating recruitment of patients was necessary for the current study to truly assess whether lowdose ESA therapy can ameliorate loss of renal function in CKD. Given the complexity of predicting which patients are likely to experience rapid decrease in eGFR, a pragmatic approach whereby renal function is screened for an extended period prior to randomization is likely to be the most effective means to identify patients with an ongoing decline in renal function. Furthermore, even with a more closely selected study population, a longer follow-up than 2 years is likely be necessary to demonstrate an effect of ESA therapy.
The study had two further weaknesses. First, despite changes to the eligibility criteria, recruitment was slower than expected, and was further compromised by supply issues with study medication. Ultimately, only 235 patients were analysed compared with the originally planned number of 400, meaning that the assumed power to detect a between-group difference in the annual change in eGFR was reduced from 90% to 80%. The situation was further complicated by the heterogeneity of the subjects in terms of baseline kidney function. The inclusion criteria stipulated that patients have CKD stage 3 at study entry, which covers . Following protocol amendments to widen the eligibility of candidates for the study, the acceptable ranges for baseline urinary albumin-creatinine ratio and urinary protein were widened, further contributing to greater renal heterogeneity in the study population. Ultimately, after unblinding it emerged that the observed SD for the annual change in eGFR was substantially higher than that assumed for the sample size calculation. The actual power to detect a between-group difference in the annual change in eGFR was therefore profoundly reduced. Future trials could benefit from narrower eligibility criteria, for example, enrolling only patients with CKD stage 3b.
Certain other features of the study should be considered. First, the study used a randomized, multicentre design with central analysis of samples. Since the primary endpoint was a laboratory value, a single-blind approach was considered sufficient, to help ensure patient compliance. Secondly, CERA dosing in the current trial took into account concerns about the safety of using high-dose ESA therapy to target aggressive Hb corridors [47] . The mean dose of $30 lg used here is lower than doses typically used for anaemia management (e.g. 50-75 lg [48] ) and was considered appropriate in view of the eligibility requirement that patients had Hb in the range 11-14 g/ dL. Accordingly, in this non-anaemic population, only a minimal change in Hb was observed in the CERA treatment arm. It should be noted that the protocol did not include an algorithm for iron therapy, and an effect of iron supplementation cannot be ruled out. Thirdly, we are aware that capture of nonendpoint data appears to have been incomplete. However, renal endpoint data were widely captured.
In summary, this population of patients with moderate CKD and Type 2 diabetes or previous kidney transplantation showed stable renal function over the course of the 2-year trial regardless of whether low-dose ESA treatment was given, with no difference in progression of albuminuria between treatment groups. Conclusions regarding the existence or non-existence of a possible renoprotective effect of ESA therapy cannot be drawn due to the absence of renal deterioration in the control arm. Any future analyses of these issues must identify patients at high risk for rapid CKD progression and, in view of the wide inter-patient variation in eGFR values observed here, may need to recruit a larger population to be adequately powered, with a longer follow-up.
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